Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity

Thrombosis Research

Volumn 121, Issue 2, 2007, Pages 145-151

  Strandberg, Karin ^a   Svensson, Peter J ^a   Öhlin, Ann Kristin ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

APC PCI complex concentration; FV Leiden; s TM activity; s TM antigen; VTE patients; VTE recurrence

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; PLASMINOGEN ACTIVATOR INHIBITOR 3; THROMBOMODULIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RISK FACTOR; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FACTOR V; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN C; PROTEIN C INHIBITOR; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THROMBOMODULIN; VENOUS THROMBOEMBOLISM;

EID: 36249018383     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.03.020     Document Type: Article

References (34)

1. Toschi V., Gallo R., Lettino M., Fallon J., Gertz S., Fernandez-Ortiz A., et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95 (1997) 594-599
2. Dahlbäck B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Int Med Res 257 (2005) 209-223
3. Stenflo J., and Dahlbäck B. Vitamin K-dependent proteins in blood coagulation. In: Stamatopolous G., Majerus P.W., Perlmutter R.M., and Varmus H. (Eds). The molecular basis of blood coagulation. Third ed (2001), W.B. Saunders 579-613
4. Esmon C.T. The endothelial protein C receptor. Thromb Haemost 83 (2000) 639-643
5. Suzuki K., Deyashiki Y., Nishioka J., and Toma K. Protein C inhibitor: structure and function. Thromb Haemost 61 (1989) 337-342
6. Huntington J.A., Kjellberg M., and Stenflo J. Crystal structure of protein C inhibitor provides insights into hormone binding and heparin activation. Structure 11 (2003) 205-215
7. Marlar R.A., Kressin D.C., and Madden R.M. Contribution of plasma proteinase inhibitors to the regulation of activated protein C in plasma. Thromb Haemost 69 (1993) 16-20
8. 2-macroblobulin in patients with disseminated intravascular coagulation. Thromb Haemost 69 (1993) 448-453
9. Espana F., Gruber A., Heeb M.J., Hansson S.R., Harker L.A., and Griffin J.H. In vivo and in vitro complexes of activated protein C with two inhibitors in baboons. Blood 77 (1991) 1754-1760
10. Laurell M., Stenflo J., and Carlsson T.H. Turnover of I-protein C inhibitor and I-alfa-1-antritrypsin and their complexes with activated protein C. Blood 76 (1990) 2290-2295
11. Strandberg K., Bhiladvala P., Holm J., and Stenflo J. A new method to measure plasma levels of activated protein C in complex with protein C inhibitor in patients with acute coronary syndromes. Blood Coagul Fibrinol 12 (2001) 503-510
12. Strandberg K., Astermark J., Björgell O., Becker C., Nilsson P.E., and Stenflo J. Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis. Thromb Haemost 86 (2001) 1400-1408
13. Tanigawa M., Wada H., Minamikawa K., Wakita Y., Nagaya A., Mori T., et al. Decreased protein C inhibitor after percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction. Am J Hematol 49 (1999) 1-5
14. Espana F., Vicente V., Tabernero D., Sharrer I., and Griffin J.H. Determination of plasma protein C inhibitor and of two activated protein C inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb Res 59 (1990) 593-608
15. Minamikawa K., Wada H., Wakita Y., Ohiwa M., Tanigawa M., Deguchi J., et al. Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism. Thromb Haemost 71 (1994) 192-194
16. Strandberg K., Kjellberg M., Erb E.M., Persson U., Mosher D.F., Villoutreix B.O., et al. Activated protein C-protein C inhibitor Complex formation: characterisation of a neoepitope provides evidence for extensive insertion of a reactive center loop. Biochemistry 39 (2000) 15713-15720
17. Strandberg K., Kjellberg M., Knebel R., Lilja H., and Stenflo J. A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma. Thromb Haemost 86 (2001) 604-610
18. Dahlbäck B., Carlsson M., and Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. PNAS 90 (1993) 1004-1008
19. Bertina R.M., Koeleman B.P.C., Koster T., Rosendaal F.R., Dirven R.J., De Ronde H., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
20. Strandberg K., Stenflo J., Nilsson C., and Svensson P.J. APC-PCI concentration is higher in patients with previous venous thromboembolism with Factor V Leiden. J Thromb Haemost 3 (2005) 2578-2601
21. Takano S., Kimura S., Ohdama S., and Aoki N. Plasma thrombomodulin in health and diseases. Blood 76 (1990) 2024-2029
22. Ishii H., Uchiyama H., and Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 65 (1991) 618-623
23. Boehme M.W., Galle P., and Stremmel W. Kinetics of thrombomodulin release and endothelial cell injury by neutrophil-derived proteases and oxygen radicals. Immunology 107 (2002) 340-349
24. Salomaa V., Matei C., Aleksic N., Sansores-Garcia L., Folsom A.R., Juneja H., et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 353 (1999) 1729-1734
25. Konstantoulas C.J., Öhlin A.-K., Humphries S.E., Goodall A.H., Toh C.-H., Mather H., et al. measurements of soluble thrombomodulin activity and antigen: factors contributing to variance and potential for identification of protein variants. Thromb Haemost 97 (2007) 161-164
26. Öhlin A.K., Larsson K., and Hansson M. Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma. J Thromb Haemost 3 (2005) 976-982
27. Öhlin A.K., Morser J., and Ohlin H. Soluble thrombomodulin antigen in plasma is increased in patients with acute myocardial infarction treated with thrombolytic therapy. Thromb Res 82 (1996) 313-322
28. Strandberg K., Svensson A., and Stenflo J. Stabilyte tubes that contain strongly acidic citrate prevents in vitro complex formation between activated protein C and protein C inhibitor. Thromb Haemost 89 (2003) 947-949
29. Faioni E.M., Franchi F., Asti D., and Mannucci P.M. Activation of the protein C pathway in hereditary thrombophilia. Thromb Haemost 80 (1998) 557-560
30. Espana F., Vaya A., Mira Y., Medina P., Estelles A., Villa P., et al. Low level of circulating activated protein C is a risk factor for venous thromboembolism. Thromb Haemost 86 (2001) 1368-1373
31. Hron G., Kollars M., Binder B.R., Eichinger S., and Kyrle P.A. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 296 (2006) 397-402
32. Nowak-Gottl U., and Vielhaber H. Elevated levels of soluble thrombomodulin in plasma from children with Arg 506 to Gln mutation in the factor V gene. Eur J Haematol 58 (1997) 51-55
33. Aleksic N., Folsom A.R., Cushman M., Heckbert S.R., Tsai M.Y., and Wu K.K. Prospective study of the A455V polymorphism in the thrombomodulin gene, plasma thrombomodulin, and incidence of venous thromboembolism: the LITE study. J Thromb Haemost 1 (2003) 88-94
34. Shrivastava S., Ridker P.M., Glynn R.J., Goldhaber S.Z., Moll S., Bounameaux H., et al. d-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost 4 (2006) 1208-1214